Completion↦Management↦Study Closure↦Notification of Closure
What is it? Why is it important?
The Ethics Committee (EC) or Regulatory Authorities (RA) such as Swissmedic (i.e. risk-category B and C studies) must be notified of study completion, discontinuation (early termination), or interruption.
A study is:
- Completed once the last study participant has completed his/her last planned visit (i.e. includes potential follow-up visits)
- Discontinued when stopped sooner than originally planned. Reasons include:
- Unexpected safety issues with a negative shift of the study`s risk-benefit ratio
- The efficacy of the investigational product (IMP/IMD) is better or worse than expected
- Temporarily Interrupted due to safety issues or concerns (i.e. regarding the risk-benefit ration of the study). The study can continue once safety issues are resolved
What do I need to do?
As a SP-INV, notify EC and if applicable Regulatory Authorities (RA) (e.g. Swissmedic, international) regarding study completion, discontinuation, or interruption.
For Investigational Medicinal Product (ClinO) studies notify:
- The EC (over BASEC) of study:
- Completion within Switzerland within 30 days
- Global completion within 90 days
- Discontinuation or interruption within 15 days
- Swissmedic (i.e. risk-category B and C) according to EC timelines
For Investigational Medical Device studies (ClinO-MD) notify:
- EC (over BASEC) of study:
- Completion, discontinuation, or interruption within 15 days.
- Discontinuation or interruption due to safety concerns within 24 hours
- Swissmedic (i.e. risk-category C) according to EC timelines
As a project leader of an HRO research project notify:
- The EC of study completion or discontinuation within 90 days
When discontinuing or interrupting a study describe:
- Reasons
- Consequences to study evaluation and results
- How many participants remain in the study (i.e. in Switzerland)
More
Notification to Swiss authorities is only applicable to studies implemented in Switzerland.
File any confirmation received by EC/RA in the trial master file (TMF) and the investigator site file (ISF) of the study. Also, in the event of multi-centre studies inform participating study sites of study closure (e.g. Site-INVs).
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissethics – see in particular
- Notification template of the completion or discontinuation of a clinical study or research project
- BASEC: EC submission portal
Swiss Law
ClinO – see in particular article
- Art. 38 Notification upon completion, discontinuation, or interruption of a study
ClinO-MD – see in particular articles
- Art. 36 Reporting the end, early termination and interruption of a clinical trial
- Art. 38 Notification and reporting to Swissmedic
HRO – see in particular article
- Art. 22, 36, 40, 43 Specifications regarding notification upon completion or discontinuation of a research project